Publications

5543 Results

Randomized, Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma: SWOG S1922

Authors
M Overman;K Guthrie;M Salem;K Pedersen;A Kalyan;S Colby;M Fakih;S Gholami;P Gold;EG Chiorean;H Hochster;PA Philip
Journal / Conference
J Clin Oncol 41, 2023 (suppl 4; abstr TPS784); ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), TIP poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S1922

SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer

Authors
V Morris;K Guthrie;S Kopetz;R Breakstone;T Karasic;Z Hu;S Colby;M Fakih;S Gholami;P Gold;P Philip
Journal / Conference
Annals of Oncology VOLUME 34, SUPPLEMENT 1, S96, JUNE 2023; ESMO World Congress on Gastrointestinal Cancer (6/28/2023 - 7/1/2023, Barcelona, Spain) TIP poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S2107

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

Authors
S Luen;G Viale;S Nik-Zainal;P Savas;R Kammler;P Dell Orto;O Biasi;A Degasperi;L Brown;I Lang;G MacGrogan;C Tondini;M Bellet;F Villa;A Bernardo;E Ciruelos;P Karlsson;P Neven;M Climent;B Muller;W Joshum;H Bonnefoi;S Martino;N Davidson;C Geyer;B Walley;J Ingle;R Coleman;C Solbach;B Thurlimann;M Colleoni;A Coates;A Goldhirsch;GF Fleming;P Francis;T Speed;M Regan;S Lori
Journal / Conference
Ann Oncol. Apr;34(4):397-409
Year
2023
Research Committee(s)
Breast
PMID
PMID36709040

Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics

Authors
L Welter;S Zheng;S Setayesh;M Morikado;A Agrawal;R Nevarez;A Naghdloo;M Pore;N Higa;A Kolatar;P Sharma;H Moore;J Richer;A Elias;K Pienta;A Zurita;M Gross;S Shishido;J Hicks;C Velasco;P Kuhn
Journal / Conference
Cancers Aug 3;15(15):3949
Year
2023
Research Committee(s)
Breast
PMID
PMID37568766
PMC
PMC10417732
Study Number(s)
S1222, S1416

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Bronchoalveolar Carcinoma of the Lung (Cohort 12)

Authors
Y Chae;M Othus;S Patel;D Gerber;T Tanvetyanon;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock
Journal / Conference
WCLC Annual Meeting (September 9-12, 2023, Singapore), poster
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (SWOG S1815; NCT#03768414)

Authors
R Shroff;K Guthrie;A Scott;M Borad;L Goff;K Matin;A Mahipal;A Kalyan;M Javle;C Aghajanian;B Tan;P Cheema;A Patel;R Iyer;R Kelley;J Thumar;A El-Khoueiry;EG Chiorean;H Hochster;PA Philip
Journal / Conference
J Clin Oncol 41, 2023 (suppl 4; abstr LBA490); ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), oral
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S1815

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The non-epithelial ovarian tumor cohort #13

Authors
Y Chae;M Othus;S Patel;K Wilkinson;E Whitman-Purves;J Lea;J Schallenkamp;N Adra;L Appleman;M Alden;J Thomes Pepin;J Ellerton;A Poklepovic;A Walter;M Rampurwala;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock
Journal / Conference
AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The small cell carcinoma of the ovary, hypercalcemic type cohort #49

Authors
Y Chae;M Othus;S Patel;R Aljumaily;K Win;T Pejovic;S Thomas;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock
Journal / Conference
AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Adjuvant everolimus in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial

Authors
PN Lara;C Tangen;E Heath;M Stein;M Meng;A Alva;S Pal;I Puzanov;J Clark;T Choueiri;N Agarwal;R Uzzo;N Haas;M Plets;U Vaishampayan;B Shuch;IM Thompson;C Ryan
Journal / Conference
Annals of Oncology VOLUME 34, SUPPLEMENT 2, S1015; ESMO (October 20-24, 2023, Madrid, Spain), poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S0931

Clinical outcomes and translational analysis of DART S1609: the thyroid cancer cohort; PD-1+ PD-L1+ TIL correlated with favorable survival

Authors
YK Chae;Y Lu;S Patel;C Rodriguez;A Onitilo;A Mattour;I Rybkin;S Fenton;L Il-Young Chung;H Kim;M Othus;E Parra;J Zhang;L Gomez;C Fernandez;L Soto;H Chen;G Manyam;D Duose;R Luthra;J Zhang;G Al-Atrash;I Wistuba;J Lee;J Zhang;C Haymaker;C McLeod;H Chen;E Sharon;C Ryan;G Lopez;M Plets;CD Blanke;R Kurzrock
Journal / Conference
SITC Annual Meeting (Nov. 1-5, 2023, San Diego, CA), poster
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609